Accelerated vs. conventionally fractionated adjuvant radiotherapy in high-risk head and neck cancer: A meta-analysis

Christiane Matuschek, Jan Haussmann, Edwin Bölke, Stephan Gripp, Patrick J. Schuler, Bálint Tamaskovics, Peter Arne Gerber, Freddy Joel Djiepmo-Njanang, Kai Kammers, Christian Plettenberg, Bahar Anooshahr, Klaus Orth, Wilfried Budach

Research output: Contribution to journalArticle

Abstract

Background: Adjuvant radiotherapy in advanced head and neck squamous cell cancer (HNSCC) reduces the risk of local-regional failure and most likely increases the survival rate. Patients at high risk for tumor recurrence may benefit from more aggressive altered fractionation schedules in order to reduce the overall time from surgery to completion of radiotherapy. Here, we reviewed the results of six randomized trials addressing the above hypothesis. Methods: In the six trials of interest, a total of 988 patients with locally advanced HNSCC were randomly assigned to receive either accelerated or conventionally fractionated adjuvant radiotherapy. Hazard ratios (HR) were extracted from available publications for local-regional control, distant metastasis as well as overall-, cancer specific- and disease-free survival. Meta-analysis of the effect sizes was performed using fixed and random effect models. Acute and late side effects were categorized and summarized for comparison. Results: Accelerated radiotherapy did not improve the loco-regional control (n = 988, HR = 0.740, CI = 0.48-1.13, p = 0.162), progression-free survival (HR = 0.89, CI = 0.76-1.04, p = 0.132) or overall survival (HR = 0.88, CI = 0.75-1.04, p = 0.148) significantly. Acute confluent mucositis occurred with significant higher frequency with accelerated radiotherapy. Late side effects did not differ significantly in either group. Conclusion: Accelerated radiotherapy does not result in a significant improvement of loco-regional control or overall survival in high-risk patients. Acute but not late radiation toxicity were more frequent with the accelerated RT technique. In clinical practice accelerated postoperative radiation therapy might be a suitable option only for a subset of patients.

Original languageEnglish (US)
Article number195
JournalRadiation Oncology
Volume13
Issue number1
DOIs
StatePublished - Oct 4 2018

Fingerprint

Adjuvant Radiotherapy
Head and Neck Neoplasms
Meta-Analysis
Radiotherapy
Squamous Cell Neoplasms
Disease-Free Survival
Head
Mucositis
Survival
Publications
Neoplasms
Appointments and Schedules
Survival Rate
Radiation
Neoplasm Metastasis
Recurrence

Keywords

  • Accelerated fractionation
  • Adjuvant therapy
  • Conventional fractionation
  • Head and neck cancer
  • High risk
  • Radiation therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Matuschek, C., Haussmann, J., Bölke, E., Gripp, S., Schuler, P. J., Tamaskovics, B., ... Budach, W. (2018). Accelerated vs. conventionally fractionated adjuvant radiotherapy in high-risk head and neck cancer: A meta-analysis. Radiation Oncology, 13(1), [195]. https://doi.org/10.1186/s13014-018-1133-8

Accelerated vs. conventionally fractionated adjuvant radiotherapy in high-risk head and neck cancer : A meta-analysis. / Matuschek, Christiane; Haussmann, Jan; Bölke, Edwin; Gripp, Stephan; Schuler, Patrick J.; Tamaskovics, Bálint; Gerber, Peter Arne; Djiepmo-Njanang, Freddy Joel; Kammers, Kai; Plettenberg, Christian; Anooshahr, Bahar; Orth, Klaus; Budach, Wilfried.

In: Radiation Oncology, Vol. 13, No. 1, 195, 04.10.2018.

Research output: Contribution to journalArticle

Matuschek, C, Haussmann, J, Bölke, E, Gripp, S, Schuler, PJ, Tamaskovics, B, Gerber, PA, Djiepmo-Njanang, FJ, Kammers, K, Plettenberg, C, Anooshahr, B, Orth, K & Budach, W 2018, 'Accelerated vs. conventionally fractionated adjuvant radiotherapy in high-risk head and neck cancer: A meta-analysis', Radiation Oncology, vol. 13, no. 1, 195. https://doi.org/10.1186/s13014-018-1133-8
Matuschek, Christiane ; Haussmann, Jan ; Bölke, Edwin ; Gripp, Stephan ; Schuler, Patrick J. ; Tamaskovics, Bálint ; Gerber, Peter Arne ; Djiepmo-Njanang, Freddy Joel ; Kammers, Kai ; Plettenberg, Christian ; Anooshahr, Bahar ; Orth, Klaus ; Budach, Wilfried. / Accelerated vs. conventionally fractionated adjuvant radiotherapy in high-risk head and neck cancer : A meta-analysis. In: Radiation Oncology. 2018 ; Vol. 13, No. 1.
@article{e8f14056914a47809af91f6134cf2183,
title = "Accelerated vs. conventionally fractionated adjuvant radiotherapy in high-risk head and neck cancer: A meta-analysis",
abstract = "Background: Adjuvant radiotherapy in advanced head and neck squamous cell cancer (HNSCC) reduces the risk of local-regional failure and most likely increases the survival rate. Patients at high risk for tumor recurrence may benefit from more aggressive altered fractionation schedules in order to reduce the overall time from surgery to completion of radiotherapy. Here, we reviewed the results of six randomized trials addressing the above hypothesis. Methods: In the six trials of interest, a total of 988 patients with locally advanced HNSCC were randomly assigned to receive either accelerated or conventionally fractionated adjuvant radiotherapy. Hazard ratios (HR) were extracted from available publications for local-regional control, distant metastasis as well as overall-, cancer specific- and disease-free survival. Meta-analysis of the effect sizes was performed using fixed and random effect models. Acute and late side effects were categorized and summarized for comparison. Results: Accelerated radiotherapy did not improve the loco-regional control (n = 988, HR = 0.740, CI = 0.48-1.13, p = 0.162), progression-free survival (HR = 0.89, CI = 0.76-1.04, p = 0.132) or overall survival (HR = 0.88, CI = 0.75-1.04, p = 0.148) significantly. Acute confluent mucositis occurred with significant higher frequency with accelerated radiotherapy. Late side effects did not differ significantly in either group. Conclusion: Accelerated radiotherapy does not result in a significant improvement of loco-regional control or overall survival in high-risk patients. Acute but not late radiation toxicity were more frequent with the accelerated RT technique. In clinical practice accelerated postoperative radiation therapy might be a suitable option only for a subset of patients.",
keywords = "Accelerated fractionation, Adjuvant therapy, Conventional fractionation, Head and neck cancer, High risk, Radiation therapy",
author = "Christiane Matuschek and Jan Haussmann and Edwin B{\"o}lke and Stephan Gripp and Schuler, {Patrick J.} and B{\'a}lint Tamaskovics and Gerber, {Peter Arne} and Djiepmo-Njanang, {Freddy Joel} and Kai Kammers and Christian Plettenberg and Bahar Anooshahr and Klaus Orth and Wilfried Budach",
year = "2018",
month = "10",
day = "4",
doi = "10.1186/s13014-018-1133-8",
language = "English (US)",
volume = "13",
journal = "Radiation Oncology",
issn = "1748-717X",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Accelerated vs. conventionally fractionated adjuvant radiotherapy in high-risk head and neck cancer

T2 - A meta-analysis

AU - Matuschek, Christiane

AU - Haussmann, Jan

AU - Bölke, Edwin

AU - Gripp, Stephan

AU - Schuler, Patrick J.

AU - Tamaskovics, Bálint

AU - Gerber, Peter Arne

AU - Djiepmo-Njanang, Freddy Joel

AU - Kammers, Kai

AU - Plettenberg, Christian

AU - Anooshahr, Bahar

AU - Orth, Klaus

AU - Budach, Wilfried

PY - 2018/10/4

Y1 - 2018/10/4

N2 - Background: Adjuvant radiotherapy in advanced head and neck squamous cell cancer (HNSCC) reduces the risk of local-regional failure and most likely increases the survival rate. Patients at high risk for tumor recurrence may benefit from more aggressive altered fractionation schedules in order to reduce the overall time from surgery to completion of radiotherapy. Here, we reviewed the results of six randomized trials addressing the above hypothesis. Methods: In the six trials of interest, a total of 988 patients with locally advanced HNSCC were randomly assigned to receive either accelerated or conventionally fractionated adjuvant radiotherapy. Hazard ratios (HR) were extracted from available publications for local-regional control, distant metastasis as well as overall-, cancer specific- and disease-free survival. Meta-analysis of the effect sizes was performed using fixed and random effect models. Acute and late side effects were categorized and summarized for comparison. Results: Accelerated radiotherapy did not improve the loco-regional control (n = 988, HR = 0.740, CI = 0.48-1.13, p = 0.162), progression-free survival (HR = 0.89, CI = 0.76-1.04, p = 0.132) or overall survival (HR = 0.88, CI = 0.75-1.04, p = 0.148) significantly. Acute confluent mucositis occurred with significant higher frequency with accelerated radiotherapy. Late side effects did not differ significantly in either group. Conclusion: Accelerated radiotherapy does not result in a significant improvement of loco-regional control or overall survival in high-risk patients. Acute but not late radiation toxicity were more frequent with the accelerated RT technique. In clinical practice accelerated postoperative radiation therapy might be a suitable option only for a subset of patients.

AB - Background: Adjuvant radiotherapy in advanced head and neck squamous cell cancer (HNSCC) reduces the risk of local-regional failure and most likely increases the survival rate. Patients at high risk for tumor recurrence may benefit from more aggressive altered fractionation schedules in order to reduce the overall time from surgery to completion of radiotherapy. Here, we reviewed the results of six randomized trials addressing the above hypothesis. Methods: In the six trials of interest, a total of 988 patients with locally advanced HNSCC were randomly assigned to receive either accelerated or conventionally fractionated adjuvant radiotherapy. Hazard ratios (HR) were extracted from available publications for local-regional control, distant metastasis as well as overall-, cancer specific- and disease-free survival. Meta-analysis of the effect sizes was performed using fixed and random effect models. Acute and late side effects were categorized and summarized for comparison. Results: Accelerated radiotherapy did not improve the loco-regional control (n = 988, HR = 0.740, CI = 0.48-1.13, p = 0.162), progression-free survival (HR = 0.89, CI = 0.76-1.04, p = 0.132) or overall survival (HR = 0.88, CI = 0.75-1.04, p = 0.148) significantly. Acute confluent mucositis occurred with significant higher frequency with accelerated radiotherapy. Late side effects did not differ significantly in either group. Conclusion: Accelerated radiotherapy does not result in a significant improvement of loco-regional control or overall survival in high-risk patients. Acute but not late radiation toxicity were more frequent with the accelerated RT technique. In clinical practice accelerated postoperative radiation therapy might be a suitable option only for a subset of patients.

KW - Accelerated fractionation

KW - Adjuvant therapy

KW - Conventional fractionation

KW - Head and neck cancer

KW - High risk

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=85054430822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054430822&partnerID=8YFLogxK

U2 - 10.1186/s13014-018-1133-8

DO - 10.1186/s13014-018-1133-8

M3 - Article

C2 - 30286777

AN - SCOPUS:85054430822

VL - 13

JO - Radiation Oncology

JF - Radiation Oncology

SN - 1748-717X

IS - 1

M1 - 195

ER -